Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)
Status:
Terminated
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The study was designed to assess whether 6 weeks of co-administration of ezetimibe and
simvastatin is more effective than simvastatin monotherapy in allowing patients in the CHD
risk strata of the NCEP III guidelines to achieve their LDL-C target goal of <=3.0 mmol/L. As
this study was to be conducted in Canada, the target LDL-C goal for patients with CHD, or
type II diabetic patients >30 years old with no CHD, was <2.5 mmol/L.